CLDX - Company ID 0000744218
The table below shows Celldex Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M | $7.42M |
| Cost of revenue | $200.00K | $200.00K | $300.00K | $100.00K | $100.00K | $200.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | $245.07M | $163.55M | $118.01M | $82.26M | $53.31M | $42.53M |
Celldex Therapeutics, Inc. reported annual revenue of $1.54M for fiscal year 2025. That is down 78.0% from $7.02M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $6.79M (FY 2016) to $1.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $43.84M |
| $38.55M |
| $30.91M |
| $27.20M |
| $20.49M |
| $14.46M |
| Operating income | -$287.37M | -$195.08M | -$154.54M | -$115.23M | -$71.24M | -$63.35M |
| Income tax | $0.00 | $0.00 | $0.00 | - | -$227.00K | -$1.17M |
| Net income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | -$70.51M | - |
| EPS (diluted) | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 |